What is a peptide?
A peptide is a short chain of amino acids joined by peptide bonds. In basic biochemistry references, peptides are usually described as shorter than large proteins.
📄 Biochemistry, Peptide — PubMedAll 62 Q&As from PepMate's Learn tab — short, plain-English answers, each linked to its PubMed source. Educational reference only: nothing here is medical advice, diagnosis, or dosing guidance.
Plain-language definitions for the terms that appear throughout peptide research.
A peptide is a short chain of amino acids joined by peptide bonds. In basic biochemistry references, peptides are usually described as shorter than large proteins.
📄 Biochemistry, Peptide — PubMedAn amino acid is a small organic building block with an amino group, a carboxyl group, and a side chain. Amino acids link together to make peptides and proteins.
📄 Biochemistry, Essential Amino Acids — PubMedA peptide bond is the covalent link between amino acids. During protein synthesis, the ribosome catalyzes peptide-bond formation as amino acids are added to a growing chain.
📄 Ten remarks on peptide bond formation on the ribosome — PubMedThe difference is mostly size and complexity. Peptides are shorter amino-acid chains, while proteins are larger folded molecules that can be made from one or more polypeptide chains.
📄 Overview of Peptides and Their Potential Roles in Skin Health and Aging — PubMedPeptides can act as signals between cells. Some regulate appetite, metabolism, blood sugar, immune activity, growth pathways, or tissue repair depending on the peptide and receptor.
📄 The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMedA peptide hormone is a peptide messenger made by the body and released to signal other tissues. Insulin, glucagon, GLP-1, and many appetite hormones are peptide hormones.
📄 Understanding peptide hormones: from precursor proteins to biological function — PubMedA receptor agonist activates a receptor and imitates or amplifies a natural signal. GLP-1 receptor agonists are one example because they activate GLP-1 receptors used in glucose and appetite regulation.
📄 GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMedGLP-1 is glucagon-like peptide-1, an incretin hormone involved in insulin release, glucagon suppression, stomach emptying, and appetite signaling after meals.
📄 The physiology of glucagon-like peptide 1 — PubMedMany peptides are broken down by digestive enzymes and have trouble crossing the intestinal wall. Injection can bypass those oral-delivery barriers.
📄 Oral delivery of peptide drugs: barriers and developments — PubMedHalf-life describes how long it takes the body to reduce a drug level by about half. Peptide drugs are often modified to last longer or clear more slowly.
📄 Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMedClinical trial phases are steps in drug development. Early phases usually focus on safety and dosing, while later phases test whether a treatment works and how safe it is in larger groups.
📄 Drug Development 101: A Primer — PubMedA placebo-controlled trial compares an active treatment with an inactive comparison treatment. Random assignment helps researchers estimate which effects are actually due to the drug.
📄 Drug Trials — PubMedWhat published trials reported when metabolic and appetite-signaling peptides were studied for weight and glucose.
Retatrutide is an investigational triple agonist that activates GIP, GLP-1, and glucagon receptors. In a phase 2 obesity trial, it produced substantial body-weight reductions over 48 weeks.
📄 Triple-Hormone-Receptor Agonist Retatrutide for Obesity — PubMedIn people with type 2 diabetes, phase 2 research reported improved glycemic control together with robust body-weight reduction. It remains a prescription-development drug, not a self-directed peptide.
📄 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — PubMedBecause weight loss and metabolic signaling can affect liver fat, retatrutide is being studied in obesity-related conditions including metabolic dysfunction-associated steatotic liver disease and steatohepatitis.
📄 Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — PubMedTirzepatide is a dual GIP and GLP-1 receptor agonist. In a 72-week obesity trial, weekly tirzepatide led to substantial and sustained weight reduction compared with placebo.
📄 Tirzepatide Once Weekly for the Treatment of Obesity — PubMedA head-to-head obesity trial reported greater body-weight and waist-circumference reductions with tirzepatide than semaglutide at week 72. Individual choice still depends on prescribing context and tolerability.
📄 Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — PubMedSemaglutide is a GLP-1 receptor agonist that reduces appetite and improves glycemic signaling. In STEP 1, weekly 2.4 mg semaglutide plus lifestyle intervention produced sustained weight loss.
📄 Once-Weekly Semaglutide in Adults with Overweight or Obesity — PubMedIn a STEP 1 extension, participants regained weight and cardiometabolic improvements moved back toward baseline after withdrawal, supporting obesity as a chronic disease needing long-term planning.
📄 Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMedLiraglutide is a daily GLP-1 receptor agonist. A large randomized weight-management trial found that 3.0 mg liraglutide with diet and exercise reduced body weight versus placebo.
📄 A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — PubMedAOD9604 is a fragment of human growth hormone studied for lipolytic and fat-metabolism effects. PubMed evidence includes animal studies showing reduced body weight and fat in obese mice.
📄 The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism — PubMedNo strong PubMed-published human efficacy base supports it for weight loss. Reviews describe AOD9604 as an obesity-drug candidate, but development did not become mainstream therapy.
📄 Obesity pharmacotherapy: current perspectives and future directions — PubMedCagrilintide is a long-acting amylin analog studied for obesity treatment. Amylin-pathway drugs can influence satiety and body-weight regulation.
📄 Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — PubMedIn a phase 3 trial, cagrilintide-semaglutide produced clinically meaningful body-weight reductions compared with placebo. Safety and approval status depend on regulatory review and prescribing context.
📄 Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — PubMedPeptides that act on the growth-hormone and IGF-1 pathway, and what the studies actually measured.
CJC-1295 is a long-acting growth-hormone-releasing hormone analog. Human pharmacology research found prolonged stimulation of growth hormone and IGF-1 after administration.
📄 Prolonged stimulation of GH and IGF-I secretion by CJC-1295 — PubMedIpamorelin is a pentapeptide growth-hormone secretagogue. Early pharmacology described it as a potent and relatively selective stimulator of growth hormone release.
📄 Ipamorelin, the first selective growth hormone secretagogue — PubMedNo. Reviews discuss ipamorelin among GH secretagogues, but that does not establish it as an anti-aging therapy. Claims should be separated from supervised endocrine indications.
📄 The role of growth hormone secretagogues in the modern clinic — PubMedTesamorelin is a growth-hormone-releasing hormone analog approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy, where trials showed reduced visceral adipose tissue.
📄 Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation — PubMedIn HIV-associated abdominal fat accumulation, a randomized study found six months of tesamorelin reduced visceral fat and produced modest liver-fat reductions.
📄 Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients — PubMedSermorelin is a growth-hormone-releasing hormone analog used mainly as a diagnostic provocative test for growth hormone deficiency, not a general wellness peptide.
📄 Sermorelin: a review of its use in the diagnosis and treatment of children with growth hormone deficiency — PubMedA multicenter study of daily GHRH(1-29) in growth-hormone-deficient children increased height velocity over one year and was reported as generally well tolerated.
📄 Once daily subcutaneous growth hormone-releasing hormone therapy in GH-deficient children — PubMedPeptides examined for skin, collagen, pigmentation, and tissue repair — often in topical or preclinical work.
GHK-Cu is a copper-binding human tripeptide studied for tissue repair, collagen support, antioxidant effects, and skin remodeling. Much of the evidence is topical or preclinical.
📄 Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — PubMedReviews report wound-healing activity in models and controlled aged-skin studies showing improvements in elasticity and appearance. This is different from proving injectable systemic benefit.
📄 The human tri-peptide GHK and tissue remodeling — PubMedMelanotan II is an alpha-MSH analog that stimulates melanocortin receptors and can increase pigmentation. A small phase 1 study also reported nausea, yawning, and spontaneous erections.
📄 Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide — PubMedThymosin beta-4 is an actin-binding peptide involved in cell migration, angiogenesis, inflammation control, and tissue repair. Much of the therapeutic evidence is experimental.
📄 Thymosin beta4: a multi-functional regenerative peptide — PubMedReviews report that thymosin beta-4 promotes cell migration and wound healing, has anti-inflammatory properties, and suppresses apoptosis in corneal and other tissue models.
📄 Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent — PubMedPepMate keeps your peptides, reminders, and injection-site notes on your device — no account, no ads. Free 3-day trial.
Neuroactive peptides explored for cognition, mood, and neuroprotection, largely in regional literature.
Semax is a synthetic ACTH fragment analog studied for neuroprotective and nootropic effects. Evidence includes mechanistic and regional clinical literature, not broad approval for cognitive enhancement.
📄 Semax, an analogue of adrenocorticotropin (4-10) — PubMedA Russian clinical study evaluated Semax during acute ischemic stroke and reported neuroprotective immune-biochemical effects. That evidence should not be generalized into unsupervised stroke prevention.
📄 Investigation of mechanisms of neuro-protective effect of Semax in ischemic stroke — PubMedSelank is a synthetic heptapeptide studied for anti-anxiety and nootropic-like effects. Most literature is mechanistic, regional, or small-scale rather than broad regulatory evidence.
📄 The Molecular Aspects of Heptapeptide Selank Biological Activity — PubMedRussian clinical literature reports anxiolytic effects in anxiety-spectrum disorders, including comparisons with phenazepam. This evidence is not the same as large international approval trials.
📄 A comparison of the anxiolytic effect and tolerability of Selank and phenazepam — PubMedPeptides studied for immune modulation and antimicrobial activity, mostly at the research stage.
Thymosin alpha-1 is an immunomodulatory peptide studied for effects on T-cell and innate immune responses, especially as an adjunct in infectious and inflammatory conditions.
📄 Thymosin alpha1 and Its Role in Viral Infectious Diseases — PubMedMeta-analyses in sepsis suggest possible mortality benefit, but authors caution about study quality and the need for stronger trials. It is not a replacement for standard infection care.
📄 The efficacy of thymosin alpha-1 as immunomodulatory treatment for sepsis — PubMedLL-37 is the only human cathelicidin antimicrobial peptide. It has broad antimicrobial activity and immune-signaling roles in skin, respiratory, gastrointestinal, and white-blood-cell biology.
📄 LL-37, the only human member of the cathelicidin family — PubMedLL-37 is promising but difficult to translate because antimicrobial peptides can face stability, delivery, and safety challenges. Current use should be considered research, not routine therapy.
📄 LL-37, the master antimicrobial peptide, its multifaceted role from infection to immunomodulation — PubMedKPV is the Lys-Pro-Val tripeptide fragment of alpha-MSH. It is studied for anti-inflammatory effects, including inhibition of inflammatory signaling in intestinal and immune cells.
📄 PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — PubMedAnimal colitis studies found KPV reduced inflammatory activity and disease severity. That makes it a research candidate, not a proven replacement for inflammatory bowel disease treatment.
📄 Melanocortin-derived tripeptide KPV has anti-inflammatory potential in colitis — PubMedWhat the literature notes about side effects, regulatory status, and the risks of unregulated use.
The most frequent adverse events in obesity trials were gastrointestinal, especially nausea, diarrhea, and vomiting. They were usually mild to moderate, but some people discontinued treatment.
📄 Tirzepatide once weekly for obesity in people with type 2 diabetes — PubMedNo. Reviews describe mostly animal and laboratory studies, with very limited human data. That makes dose, product quality, and long-term safety uncertain outside regulated research.
📄 Emerging Use of BPC-157 in Orthopaedic Sports Medicine — PubMedBPC-157 is not FDA-approved, and sports-medicine reviews note concerns around unregulated production, limited clinical safety data, and restrictions in sport settings.
📄 Emerging Use of BPC-157 in Orthopaedic Sports Medicine — PubMedIt stimulates the GH/IGF-1 axis, which can affect glucose metabolism, fluid retention, and hormone-sensitive conditions. It is also considered a prohibited GH-releasing substance in sport.
📄 Identification of CJC-1295, a growth-hormone-releasing peptide — PubMedUnregulated Melanotan II use has been associated with melanocytic changes, pigmentation changes, toxicity reports, and melanoma case reports. It is not a safe substitute for sun protection.
📄 Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues — PubMedMelanocortin agonism can influence sexual arousal pathways. Human research reported more sexual desire and erections with Melanotan II than placebo, but nausea and yawning were frequent.
📄 Melanocortin receptor agonists, penile erection, and sexual motivation — PubMedReviews describe gastrointestinal effects, especially nausea and vomiting, as the most common adverse effects, often occurring early in treatment.
📄 Liraglutide for weight management: a critical review of the evidence — PubMedBremelanotide is a melanocortin receptor agonist studied and approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
📄 Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder — PubMedBoth affect melanocortin pathways, but bremelanotide is a regulated drug for a specific sexual-desire indication, while Melanotan II is commonly sold unlicensed for tanning.
📄 New Drug Approved for Treating Hypoactive Sexual Desire Disorder — PubMedEarlier-stage peptides where the human evidence is still limited, mixed, or emerging.
BPC-157 is studied mostly as a regenerative and cytoprotective peptide. PubMed reviews describe promising tissue-repair effects in preclinical models, but clinical evidence remains limited.
📄 Regeneration or Risk? A Narrative Review of BPC-157 — PubMedMOTS-c is a mitochondrial-derived peptide that can move to the nucleus during metabolic stress and influence gene expression related to cellular and metabolic homeostasis.
📄 MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — PubMedNo approved human therapeutic use is established. Human studies mainly examine circulating MOTS-c relationships with metabolic markers, while many intervention claims come from animal or cell work.
📄 Plasma MOTS-c levels are associated with insulin sensitivity in lean but not obese individuals — PubMedEpitalon is a synthetic pineal tetrapeptide studied in aging and telomere biology. Newer work reports telomere-length effects in human cell lines, not proof of human anti-aging benefit.
📄 Epitalon increases telomere length in human cell lines — PubMedEvidence is mixed and not clinically definitive. A mouse biomarker study reported that Epitalon did not influence food consumption, body weight, or mean life span.
📄 Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence — PubMedKisspeptin is a reproductive neuropeptide that stimulates gonadotropin release through GnRH pathways. Human studies show responses vary by sex and menstrual-cycle phase.
📄 The effects of kisspeptin-10 on reproductive hormone release — PubMedBecause kisspeptin controls reproductive hormone signaling, agonists are being studied for female reproductive disorders and ovulation-related treatment strategies.
📄 Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders — PubMedPepMate keeps your peptides, reminders, and injection-site notes on your device — no account, no ads. Free 3-day trial.